Background {#Sec1}
==========

The number of adults with diabetes mellitus (DM) worldwide was estimated to be 366 million in 2011 and is expected to reach 552 million by 2030 \[[@CR1], [@CR2]\]. The International Diabetes Federation has estimated that 50% of adults with diabetes are undiagnosed \[[@CR3]\]. DM is also highly prevalent in China and is a great disease burden \[[@CR4]\]. Lowering low-density lipoprotein cholesterol (LDL-C) has been considered to be essential in preventing cardiovascular disease \[[@CR5]\]. However, statin therapy has been associated with a slightly increased risk of DM despite unknown clinical significance. \[[@CR6], [@CR7]\] The relationship between statins and DM is also subject to "reverse epidemiology" or the "risk factor paradox" observed in obese or geriatric populations \[[@CR8], [@CR9]\]. In China, low LDL-C levels appeared to associate with an increased risk of intracerebral hemorrhage \[[@CR10]\], while high triglycerides (TG) associated with a decreased risk of cognitive decline and daily activity, as well as an increased risk of frailty and mortality in elderly \[[@CR11]\]. Meanwhile, data from representative cross-sectional studies in the USA and Spain indicated an positive association between LDL-C levels and body mass index (BMI) only in lean individuals \[[@CR12]\]. Moreover, lipid paradox have been observed in hypertensive populations \[[@CR13]--[@CR15]\]. In addition to obesity, hypertension may also affect cholesterol metabolism, but the impact of LDL-C on DM occurrence has received less attention, particularly among patients with hypertension.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

We enrolled 10,322 participants over 18 years of age who were included in a registry of hypertensive patients in Dongguan, Guangdong, China in 2015. A total of 9892 patients with a complete set of data were included in the analysis. The present study complied with the ethical principles of the Declaration of Helsinki and was approved by the institutional medical ethical committee at Guangdong General Hospital, Guangzhou, China. All enrolled participants have provided written informed consent.

Collection of participant data {#Sec4}
------------------------------

A structured questionnaire was administered by trained staff to obtain participants' age, sex, smoking status, alcohol consumption, medical history including coronary artery disease (CAD), DM, and stroke, and medication history including the use of β-blockers, calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI) / angiotensin-receptor blockers (ARB), and statins. Participants' height, weight, waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), estimated glomerular filtration rate (eGFR), and BMI (kg/m^2^) were assessed. eGFR was calculated as 186 × Scr^− 1.154^ × age^− 0.203^ × 0.724 for women; Scr is serum creatinine (mg/dL). Following the 2010 Chinese guidelines for the management of hypertension \[[@CR16]\], hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, and/or use of antihypertensive medications within 2 weeks of enrollment. Participants were considered to have DM if they had previously been diagnosed by a registered medical practitioner, and/or had used hypoglycemic drugs within 2 weeks, and/or had a baseline FBG ≥ 7.0 mmol/l. Dyslipidemia was defined as TC ≥ 6.2 mmol/L (high TC), and/or TG ≥ 2.3 mmol/L (high TG), and/or LDL-C (high LDL-C) ≥ 4.1 mmol/L, and/or HDL-C \< 1.0 mmol/L (low HDL-C), and/or use of lipid-lowering medications \[[@CR17]\].

Statistical analysis {#Sec5}
--------------------

Categorical variables were reported as numbers and percentages and compared by the *χ*^*2*^ test. Continuous values were reported as means ± standard deviation and compared using the Kruskal--Wallis test or one-way analysis of variance. Logistic regression was used to estimate the association between LDL-C level and DM in all participants. The study participants were stratified into three groups by their LDL-C levels, namely desirable (\< 3.4 mmol/L), borderline high (3.4 to 4.1 mmol/L) and high (\> 4.1 mol/L) as defined according to the 2016 Chinese guidelines for the management of dyslipidemia in adults \[[@CR17]\]. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence Intervals (CIs) of DM in each group. Logistic regression was also used to calculate the *p-values* for trends of the quartiles in each LDL-C concentration. We have built 3 regression models for each stratum of LDL-C concentration. Model 1 only included LDL-C concentration, model 2 was additionally adjusted for age and sex, and model 3 was additionally adjusted for smoking status, alcohol consumption, history of CAD and stroke, use of *β*-blockers, CCB, ACEI/ARB, statins, BMI, WC, SBP, DBP, TG, HDL-C and eGFR. The shape of association between LDL-C levels and DM was examined by restricted cubic spline regression models. The interactions of LDL-C level with age, sex, smoking, alcohol consumption, history of CAD or stroke, statin usage and BMI were evaluated by interaction tests. Multiple imputation based on five replications and a chained equation method using the R statistics "mice" package was used to account for missing data with 1234 as a random number seed \[[@CR18]\]. *P* values less than 0.05 were considered statistically significant. R 3.5.1 (<https://cran.r-project.org/mirrors.html>) was used for all statistical analysis.

Results {#Sec6}
=======

Participant characteristics {#Sec7}
---------------------------

Table [1](#Tab1){ref-type="table"} shows the demographic characteristics of the 9892 participants stratified by their LDL-C levels. The participants included 4921 men, and were 62.9 ± 13.7 years of age, 23.7% of them had DM and 58.7% had dyslipidemia. Participants with LDL-C concentrations ≥4.1 mmol/L were on average older in age, higher proportion being women, and had higher WC, SBP, TC, TG, HDL-C, and FBG values, higher prevalence of DM and CAD, and lower baseline eGFR than participants with LDL-C concentrations 3.4--4.1 mmol/L. Participants with LDL-C concentrations \< 3.4 mmol/L were younger in age, had higher FBG, lower WC and SBP than participants in other two groups, and higher prevalence of DM or CAD. Table 1Participants characteristicsCharacteristicsOverallLDL-C, mmol/L\< 3.43.4 to 4.1≥4.1*P*-valueNo. of participants9892503828472007Demographics Age, y62.9 ± 13.761.9 ± 14.362.9 ± 13.465.2 ± 12.4\< 0.001 Male4921 (49.7%)2651 (52.6%)1420 (49.9%)850 (42.4%)\< 0.001 Smoking2622 (26.5%)1328 (26.4%)773 (27.2%)521 (26.0%)0.615 Alcohol use1388 (14.0%)686 (13.6%)452 (15.9%)250 (12.5%)0.002 BMI, kg/m224.8 ± 3.8524.8 ± 3.8924.8 ± 3.7525.0 ± 3.900.028 Waist circumference88.0 ± 9.6387.8 ± 9.7988.0 ± 9.4088.6 ± 9.520.016Comorbidity Stroke205 (2.1%)134 (2.7%)45 (1.6%)26 (1.3%)\< 0.001 Coronary artery disease161 (1.6%)103 (2.0%)26 (0.9%)32 (1.6%)\< 0.001 Diabetes mellitus2341 (23.7%)1298 (25.8%)599 (21.0%)444 (22.1%)\< 0.001 Dyslipidemia5811 (58.7%)2604 (51.7%)1200 (42.1%)2007 (100%)\< 0.001  TC ≥ 6.2 mmol/L1995 (20.2%)85 (1.7%)344 (12.1%)1566 (78.0%)\< 0.001  TG ≥ 2.3 mmol/L2165 (21.9%)1047 (20.8%)647 (22.7%)471 (23.5%)0.021  HDL-C \< 1.0 mmol/L1288 (13.0%)888 (17.6%)291 (10.2%)109 (5.4%)\< 0.001Medication β-blockers721 (7.3%)439 (8.7%)168 (5.9%)114 (5.7%)\< 0.001 Calcium channel blockers3139 (31.7%)1730 (34.3%)882 (31.0%)527 (26.3%)\< 0.001 ACEI/ARB4315 (43.6%)2417 (48.0%)1156 (40.6%)742 (37.0%)\< 0.001 Statin1898 (19.2%)1415 (28.1%)316 (11.1%)167 (8.3%)\< 0.001Blood pressure, mm Hg Systolic132 ± 16.2131 ± 15.8132 ± 16.3133 ± 17.0\< 0.001 Diastolic80.8 ± 15.180.5 ± 14.181.4 ± 18.980.7 ± 11.10.04Biomarkers TC,mmol/L5.31 ± 1.164.51 ± 0.7425.66 ± 0.5586.83 ± 0.866\< 0.001 TG,mmol/L1.83 ± 1.581.82 ± 1.731.83 ± 1.371.88 ± 1.46\< 0.001 LDL-C,mmol/L3.40 ± 0.9272.69 ± 0.4833.72 ± 0.2214.75 ± 0.586\< 0.001 HDL-C,mmol/L1.35 ± 0.3651.32 ± 0.3651.35 ± 0.3181.41 ± 0.419\< 0.001 FBG,mmol/L5.35 ± 1.815.35 ± 1.795.27 ± 1.685.47 ± 2.050.007 eGFR,ml/min/1.73m^2^88.4 ± 26.089.4 ± 27.488.3 ± 24.886.0 ± 24.0\< 0.001BMI indicates body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; FBG, fasting blood glucose; eGFR, estimated glomerular filtration rateValues for categorical and continuous variables are given as numbers (percentages) and as means ± standard deviation, respectively

Association between LDL-C and DM {#Sec8}
--------------------------------

Logistic regression found an inverse association between LDL-C and DM but the association was U-shaped after stratification when including LDL-C as a continuous or categorical variable. For participants with LDL-C concentrations \< 3.4 mmol/L, there was an inverse association between the lowest quartile of LDL-C and DM likelihood in all regression models when using the highest quartile as referent. For participants with borderline high LDL-C, the highest quartile of LDL-C associated with a lower DM prevalence comparing with the lowest quartile. In participants with high LDL-C concentrations, the highest quartile of LDL-C associated with a higher DM likelihood comparing with the lowest quartile (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). The *p*-value for trend was significant in all regression models except for model 3 of participants with borderline high LDL-C. The results of a restricted cubic spline regression shown in Fig. [1](#Fig1){ref-type="fig"} revealed a U-shaped relationship of DM prevalence with increasing LDL-C after adjusting for all covariates. Table 2Logistic OR (95% CIs) for diabetes mellitus and continuous measures of LDL-CNo. of participantsmodel1model2model3Overall (per 1 mmol/L increase)98920.88(0.837,0.926)\*\*0.893(0.848,0.94)\*\*0.944(0.893,0.998)\*\*Per 1 mmol/L decrease in first group (LDL-C \< 3.4 mmol/L)50381.364(1.201,1.550)\*1.380(1.213,1.569)\*1.240(1.076,1.429)\*\*Per 1 mmol/L increase in second group(3.4 ≤ LDL-C \< 4.1 mmol/L)28470.657(0.436,0.990)\*0.700(0.463,1.057)\*0.746(0.485,1.149)Per 1 mmol/L increase in third group (LDL-C ≥ 4.1 mmol/L)20071.270(1.073,1.503)\*\*1.489(1.108,2.003)\*\*1.536(1.126,2.096)\*\*model1, unadjusted;model2, adjusted for age, sex;model3, adjusted for age, sex,smoking, alcohol consumption, history of CAD, stroke, consumption of β-blockers, calcium channel blockers, ACEI/ARB, statin, BMI, SBP, DBP, TG, HDL-C and eGFR;\**p* \< 0.05, \*\**p* \< 0.01;OR, odds ratio; CIs, confidence Intervals Table 3Logistic OR (95% CIs) for diabetes mellitus and LDL-C stratified by quartilecase/totalmodel1model2model3OR(95%CIs)*p*-valueOR(95%CIs)*p*-valueOR(95%CIs)*p*-valueLDL-C \< 3.4 mmol/L,*n* = 5038Q1337/12601.425(1.192,1.702)\< 0.0011.441(1.205,1.723)\< 0.0011.248(1.026,1.517)0.027Q2332/12591.195(0.997,1.433)0.0541.194(0.996,1.432)0.0561.146(0.944,1.391)0.168Q3298/12571.037(0.862,1.247)0.7011.026(0.853,1.235)0.7841.031(0.848,1.253)0.761Q4291/1262refrefrefP for trend\< 0.001\< 0.0010.0153.4 mmol/L ≤ LDL-C \< 4.1 mmol/L,*n* = 2847Q1171/712refrefrefQ2142/7120.795(0.618,1.022)0.0740.814(0.632,1.049)0.1120.806(0.618,1.051)0.111Q3154/7120.880(0.687,1.128)0.3130.899(0.700,1.153)0.4010.936(0.721,1.215)0.619Q4131/7110.708(0.548,0.915)0.0080.735(0.568,0.951)0.0190.753(0.575,0.986)0.039P for trend0.0230.0470.105LDLC ≥4.1 mmol/L,*n* = 2007Q1103/502refrefrefQ2103/5021.012(0.746,1.374)0.9381.043(0.766,1.42)0.7890.999(0.721,1.383)0.994Q3102/5010.990(0.729,1.346)0.9501.005(0.737,1.37)0.9750.990(0.715,1.371)0.951Q4135/5021.425(1.063,1.910)0.0181.489(1.108,2.003)0.0081.536(1.126,2.096)0.007P for trend0.0240.0130.008model1, unadjusted;model2, adjusted for age, sex;model3, adjusted for age, sex, smoking, alcohol consumption, history of CAD, stroke, consumption of β -blockers, calcium channel blockers, ACEI/ARB, statin, BMI, SBP, DBP, TG, HDL-C and eGFR;*OR,* odds ratio, *CIs,* confidence Intervals Fig. 1Restricted cubic spline of low-density lipid cholesterol levels and diabetes mellitus. Adjusted for age, sex, smoking, alcohol consumption, history of CAD and stroke, consumption of β-blockers, CCB, ACEI/ARB, statin, BMI, WC, SBP, DBP, TG, HDL-C and eGFR. The solid curve shows the association between LDL-C levels and DM. The histograms below show the distributions of LDL-C level in the populations

Subgroup analysis {#Sec9}
-----------------

The associations between LDL-C and DM likelihood were stratified by participants' age, sex, smoking status, alcohol consumption, history of CAD or stroke, BMI, and statin use (Table [4](#Tab4){ref-type="table"}). In patients with desirable LDL-C levels, the inverse association between LDL-C and DM was significantly modified by age and history of stroke (*p* for interaction both \< 0.05). In participants with high LDL-C levels, the positive association between LDL-C and DM was modified by the use of statins (*p* for interaction = 0.049). Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1 shows that imputation of missing covariate data did not lead to any substantial changes in the results of the analysis. Table 4Association between LDL-C levels and diabetes mellitus among subgroupssubgroupLDL-C \< 3.4 mmol/L3.4 mmol/L ≤ LDL-C \< 4.1 mmol/LLDLC ≥4.1 mmol/LOR(95%CIs)*P*-valueP-interactionOR(95%CIs)*P*-valueP-interactionOR(95%CIs)*P*-valueP-interactionAge,y0.0220.1190.648≥600.778(0.642,0.944)0.0110.603(0.332,1.094)0.0961.316(1.045,1.656)0.019\< 600.827(0.657,1.040)0.1040.885(0.440,1.779)0.7311.45(1.044,2.012)0.026Sex0.7710.3580.197Male0.774(0.633,0.946)0.0120.913(0.48,1.735)0.781.528(1.153,2.026)0.003Female0.862(0.703,1.057)0.1520.616(0.34,1.115)0.111.202(0.949,1.524)0.127Smoke0.6950.1960.265Yes0.658(0.490,0.885)0.0061.131(0.489,2.615)0.7731.580(1.096,2.277)0.014No0.840(0.713,0.989)0.0360.619(0.372,1.029)0.0641.240(1.008,1.525)0.041Alcohol consumption0.3330.3950.399Yes0.645(0.428,0.972)0.0361.166(0.344,3.952)0.8051.489(0.849,2.612)0.165No0.831(0.713,0.967)0.0170.702(0.440,1.12)0.1371.285(1.063,1.555)0.01CAD0.2930.1140.639Yes0.967(0.265,3.531)0.9590.186(0,Inf)10.195(0,Inf)1No0.802(0.695,0.926)0.0030.777(0.504,1.199)0.2551.32(1.102,1.581)0.003Stroke0.0050.2190.126Yes3.547(1.236,10.181)0.0190.000(0.000,50.287)0.1230(0,Inf)1No0.775(0.671,0.895)0.0010.763(0.494,1.179)0.2231.288(1.076,1.542)0.006BMI, kg/m20.4110.0990.417≥240.827(0.691,0.990)0.0390.764(0.448,1.302)0.3221.349(1.083,1.681)0.008\< 240.993(0.914,1.079)0.8690.597(0.273,1.306)0.1971.314(0.952,1.815)0.097Statin0.6220.7480.049Yes0.996(0.990,1.002)0.2071.000(0.969,1.031)0.9821.027(1.009,1.045)0.003No0.994(0.989,0.999)0.0100.992(0.981,1.004)0.2161.005(1.000,1.010)0.034LDL-C,low density lipoprotein-cholesterol, CAD, coronary artery disease, BMI, body mass index, OR, odds ratio; CIs, confidence Intervalsmodel adjusted for age, sex, smoking, alcohol consumption, history of CAD, stroke, consumption of β-blockers, calcium channel blockers, angiotensin-converting enzyme /angiotensin-receptor blockers, statin, BMI, systolic blood pressure, diastolic blood pressure, TG, HDL-C and estimated glomerular filtration rate

Discussion {#Sec10}
==========

The present study revealed a U-shaped association between LDL-C levels and the chance of DM among hypertensive participants in China. Among participants with desirable LDL-C concentration and aged over 60, LDL-C was protective against DM. Among participants with high LDL-C concentration, LDL-C increased the likelihood of DM even with the use of statin. The applicability of reducing LDL-C as much as possible may vary by age, stroke history and the use of statin.

The inverse association between LDL-C level and DM among participants with desirable LDL-C concentration may be related to statin therapy. Statin therapy was associated with a 9% increased risk of incident DM, with the effect being stronger in older individuals \[[@CR6]\]. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) increases the expression of LDL receptors in many tissues and promotes transmembrane cholesterol transport. This alteration in cholesterol transport may be involved in the pathogenesis of diabetes \[[@CR19]\]. Nevertheless, after stratifying by the use of statin, multivariable logistic regression found that the relationship between DM and LDL-C was not affected by statins. Genetic studies have shown that the incidence of new-onset DM is associated with low LDL-C levels \[[@CR19], [@CR20]\], which are consistent with a previous finding that patients with familial hypercholesterolemia were less likely to have type 2 diabetes \[[@CR21]\]. In addition, overexpression of Niemann-Pick C1-like 1 (*NPC1L1*), an inhibitor of the LDL-C transporter, may suppress gluconeogenesis. In contrast, inhibiting *NPC1L1* by ezetimibe, a lipid-lowering agent, may increase gluconeogenesis \[[@CR22]\].

Overweight and obesity may have influenced the associations between LDL-C and the likelihood of DM. The average BMI of our participants with desirable LDL-C concentration was approximately 25 kg/m^2^. Insulin resistance is physiologically linked with body weight gain, while statins was also associated with increased BMI and body weight gain hence the incidence of DM in a previous study \[[@CR23]\]. It was also reported that LDL-C decreased among participants with BMIs \> 27 kg/m^2^ \[[@CR12]\], indicating that the reverse relationship between decreased LDL-C levels and DM in participants with desirable LDL-C levels may have been associated with high BMIs. Adipocytes are passive energy storage tissues that produce adipocytokines that protect against the establishment of insulin resistance in the liver and skeletal muscle. Obesity or insulin resistance may result in decreased lipid deposition leading to consistent reduction in LDL-C particle formation \[[@CR24]\].

Moreover, age may have affected the relationship between LDL-C levels and the chance of getting DM. Changes in TC, TG and LDL-C levels that occur in the geriatric population have been inversely associated with all-cause mortality. The association might be a result of decreased cellular antioxidant capacity and LDL-C production described in the free-radical theory of aging (FRTA) \[[@CR25]--[@CR28]\]. However, the relationship between LDL-C levels and DM in geriatric populations has not been reported. We found a inverse association between LDL-C and DM in older, hypertensive participants with low LDL-C levels, but it is not clear whether FRTA can account for this relationship.

Hypertensive patients with LDL-C levels ≥4.1 mmol/L had an increased chance of having DM. A longitudinal study in Iran found that a high LDL-C level was significantly associated with increased risk of new-onset DM, which is consistent with our results \[[@CR29]\]. In this study, the impact of higher LDL-C levels on DM likelihood was stronger in participants who were using statins than in those who were not. The result indicates that the increase of prevalent DM in participants using statins may not have been associated with decreased LDL-C levels. The association between LDL-C levels ≥4.1 mmol/L and an increased chance of DM may result from an interaction of health status with changes in metabolism. The physiology of that relationship needs further investigation.

The main strength of our study is that we fitted restricted cubic spline models to demonstrate a U-shaped association between LDL-C levels and DM. However, the limitation of this study was the use of cross-sectional data. Further longitudinal studies are needed to verify the associations that we found. Secondly, there might have residual confounding effects because DM is a multifactorial, heterogeneous disease. Thirdly, findings in this population is not generalizable to people with different ethnic backgrounds and disease status. Fourthly, we did not assess different types of DM and how it might relate to cholesterol metabolism.

Conclusion {#Sec11}
==========

This cross-sectional study found a U-shaped relationship between LDL-C levels and the likelihood of DM in a Chinese registry of hypertensive patients. LDL-C was protective against DM in patients with concentrations of \< 3.4 mmol/L, but increased the chance of having DM in those with high LDL-C concentrations.

Additional file
===============

 {#Sec12}

Additional file 1:**Table S1.**Logistic OR (95% CIs) for diabetes mellitus and continuous measures of LDL-C with multiple imputation data, *n* = 10,322 (XLSX 9 kb)
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